英国富时100指数跌0.23%，法国CAC40指数涨0.21%，德国DAX30指数涨0.46%，欧洲斯托克50指数涨 0.07%。 英国富时100指数跌0.23%，法国CAC40指数涨0.21%，德国DAX30指数涨0.46%，欧洲斯托克50指数涨 0.07%。 ...

瑞银预测，2026年港股IPO数量将达150家至200家，募资额将超3000亿港元。 中资企业蜂拥赴港上市，IPO大单频现，走过火热的2025年，港股IPO在2026年能否延续强劲势头？ "我们认为，港股IPO的热度在今年能够得以延续，基础支撑是存在的。"瑞银集团中国区总裁及瑞银证 券董事长胡知鸷对第一财经表示，中国香港的全球领先国际金融中心地位、港股IPO排队企业数量充足 等，将共同支撑港股IPO继续走热。 瑞银预测，2026年全年，港股上市企业数量将达到150家至200家，募资额有望超过3000亿港元。 从基石投资者参与热度来看，港股IPO项目仍备受追捧。就在本周，MiniMax（稀宇科技）将于1月9日 登录港交所，其吸引了14名基石投资者，包括Aspex、Eastspring、阿里巴巴、易方达等，认购总额约 27.23亿港元，占到募资总额的六成以上。 胡知鸷观察到，此前，部分海外项目发行难度较高，因此需要有一定比例的基石投资者，以增加发行确 定性。"现在这种情况反过来了，是投资人要去争当基石，或者锚定（投资者），核心原因只有一个， 怕抢不到单。" "抢着要做基石" 就在几天前，2025年收官之际，港交所 ...

Group 1 - Southbound funds recorded a net purchase of 9.178 billion HKD today [1] - Tencent Holdings, Xiaomi Group-W, and the Tracker Fund of Hong Kong were the top three net purchases, with net buys of 1.955 billion HKD, 1.633 billion HKD, and 1.465 billion HKD respectively [1] - On the sell side, China Mobile, SMIC, and Kuaishou-W experienced net sales of 1.126 billion HKD, 1.070 billion HKD, and 0.157 billion HKD respectively [1]

Core Viewpoint - The company Yiming Oncology (01541.HK) has decided to terminate its licensing agreement with Axion for the development and commercialization rights of two products, IMM2510 and IMM27M, outside Greater China, reclaiming all rights previously granted [2][3]. Group 1: Termination of Licensing Agreement - Yiming Oncology announced the termination of its licensing agreement with Axion on January 6, 2026, which included the global development and commercialization rights for IMM2510 and IMM27M outside Greater China [2]. - The initial collaboration began in August 2024, with the agreement valued at over $2 billion [2]. Group 2: Financial Implications - The termination of the agreement does not affect the $35 million upfront and milestone payments already received from Axion [3]. - The company expressed confidence in the therapeutic potential of IMM2510 and IMM27M and aims to accelerate their clinical development [5]. Group 3: Reasons for Reclaiming Rights - The CEO of Yiming Oncology stated that the collaboration with Axion had been positive, but clinical progress was slow due to funding pressures, prompting shareholders to suggest reclaiming the overseas rights [3]. - The complexity of negotiating with both Axion and potential partners hindered business development efforts, which the company hopes to simplify by reclaiming the rights [5]. Group 4: Market Context - The PD-1/VEGF dual antibody market has seen significant activity, with other companies securing large licensing deals, such as $1.25 billion for a similar product from a Chinese company [4]. - The market environment in early 2025 was characterized by high transaction prices for PD-1/VEGF deals, which may have influenced the decision to reclaim the rights [5].

(本文来自第一财经) 南京熊猫发布异动公告称，公司关注到近期脑机接口概念引发市场广泛关注，现作如下说明：公司主营 业务聚焦智慧交通与平安城市、工业互联网与智能制造、绿色服务型电子制造三大领域，目前未发生任 何变化。截至目前，公司尚无与脑机接口相关的成熟产品，亦未形成相关销售收入，相关概念不会对公 司当前生产经营活动产生实质性影响。 ...

高能环境发布2025年度业绩预告，预计归属于上市公司股东的净利润为7.50亿元至9.00亿元，同比增长 55.66%到86.79%。 ...

（文章来源：第一财经） 泰胜风能在互动平台表示，公司积极推动商业航天业务的开拓，与多家整箭制造商开展基于技术研发的 战略合作。 ...

Core Viewpoint - The company Yiming Anke has decided to terminate its licensing agreement with Axion for two drug candidates, IMM2510 and IMM27M, and will reclaim all rights previously granted to Axion, including global development and commercialization rights outside Greater China [1] Group 1: Licensing Agreement Details - The initial licensing agreement with Axion began in August 2024, with a collaboration amount exceeding $2 billion [1] - Yiming Anke has received a total of $35 million in upfront and milestone payments from Axion prior to the termination of the agreement [1] Group 2: Reasons for Termination - The CEO of Yiming Anke stated that the collaboration with Axion had been pleasant, but the slow clinical progress due to funding constraints led to the decision to reclaim the rights [1] - Shareholders had been advising the company to reclaim the overseas rights for the two products, making this an opportune moment for the company [1] Group 3: Product Information - IMM2510 is a PD-L1/VEGF bispecific antibody, which is a significant target in tumor immunotherapy, and its potential to disrupt the PD-1 market is highly anticipated [2] - The market for PD-1/VEGF bispecific antibodies has seen increased activity since 2024, with notable deals such as the $1.25 billion upfront payment received by a competitor for a similar product [2] Group 4: Future Plans - Yiming Anke expressed confidence in the therapeutic potential of IMM2510 and IMM27M and aims to accelerate their clinical development [3] - The company plans to seek new business development partnerships with large multinational pharmaceutical companies, which will be simplified by reclaiming the rights from Axion [3]

中航光电在互动平台表示，公司目前针对机器人领域已具备成熟的互连解决方案。 ...

以前个人自行申报缴纳增值税，而今年起付钱的单位需要替个人代扣代缴增值税，此前一些个人偷税情 形或不复存在。 今年起增值税法和增值税实施条例正式施行。其中，增值税法实施条例明确，自然人发生符合规定的应 税交易，支付价款的境内单位为扣缴义务人。代扣代缴的具体操作办法，由国务院财政、税务主管部门 制定。 上海国家会计学院副教授葛玉御告诉第一财经，以前个人要去税务局代开发票来缴纳增值税，但实际上 因各种原因，部分个人并没有缴税，而支付价款单位也没有代扣代缴义务。但今年起随着上述增值税法 实施条例实施，自然人增值税征管有了创新，引入了"支付方代扣代缴义务"，以后境内单位就需要给个 人代扣代缴增值税。这将与"劳务费反向申请代开发票"形成组合拳，意味着对自然人的税收征管在逐步 加强。 葛玉御举例，比如专家教授给高校、企业授课，高校、企业给他支付劳务报酬，这属于典型的增值税应 税服务，未来单位不仅要代扣代缴个人所得税，还得代扣代缴增值税。 所谓代扣代缴指税收法律、行政法规明确规定的扣缴义务人，在支付款项时代税务机关从纳税人收入中 扣留并解缴税款的征管方式。比如很多企事业单位职工熟悉的单位代扣代缴个人所得税。 "而今年起增值税 ...